Catalyst ligands

78902-09-7, 2-(2,2-Diethoxyethyl)isoindoline-1,3-dione is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2-{2,2-bis[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]ethyl}-1H-isoindole-1,3(2H)-dione (Compound 5) To a mixture of phthalimidoacetaldehyde diethyl acetal (3.5 g, 13.3 mmol) and cis,cis-9,12-octadecadien-1-ol (10.6 g, 39.9 mmol) was added pyridinium p-toluenesulfonate (0.167 g, 0.665 mmol) and heated to 105 C. After 48 h, the reaction was diluted in 300 ml of dichloromethane. The organic was washed by 100 ml of saturated sodium bicarbonate solution twice and brine (100 ml). The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (0% ethyl acetate/hexane ?20% ethyl acetate/hexane) to give the title compound (7.6 g). MS 726.6 (M+Na).

78902-09-7 2-(2,2-Diethoxyethyl)isoindoline-1,3-dione 315286, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; SIRNA THERAPEUTICS, INC.; Colletti, Steven L.; Deng, Zhengwu James; Stanton, Matthew G.; Wang, Weimin; Hills, Ivory; (47 pag.)US9670487; (2017); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.54761-04-5,Ytterbium(III) trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

To 5 (0.131 g, 1.0 mmol) and Yb(OTf)3 (0.124 g, 0.20 mmol) in CH2Cl2 (1.5 mL) under argon was added methyl vinyl ketone 22(0.162 mL, 2 mmol). The reaction mixture was stirred at rt overnight and concentrated in vacuo. Purification by silica gel chromatography (1:1, EtOAc:hexane, to 100%, EtOAc, as eluent) afforded 24 asa white solid (0.051 g, 25%) and 23 as a yellow oil (0.128 g, 37%): Rf.0.23 (1:1, EtOAc:methanol, as eluent); 1H NMR (700 MHz, CDCl3)d 9.12 (br s, 1H), 7.87 (dd, J7.6, 1.1 Hz, 1H), 7.72 (td, J7.6, 1.1 Hz,1H), 7.47 (td, J7.6, 1.1 Hz, 1H), 7.35 (dd, J7.6, 1.1 Hz, 1H), 4.32 (t,J6.0 Hz, 2H), 4.14 (t, J8.1 Hz, 2H), 3.29 (t, J6.0 Hz, 2H), 3.27 (t,J8.1 Hz, 2H), 2.23 (s, 3H) ppm; 13C NMR (176 MHz, CDCl3) d 206.2,168.1, 138.6, 136.4, 134.7, 128.7 (q, J285 Hz), 124.7, 121.9, 119.4,116.8, 55.6, 49.2, 40.1, 30.1, 25.5; IR nmax (thin film) 1714 (C]O),1661 (C]N) cm1; LRMS (TOF ES), 203.5 (100%) [MH], 201.7(70%), 132.1 (25%); LRMS (TOF ES-), 149.0 (100%) [OTf]; HRMS(FTMS ES) calculated for C13H15NOH, 202.12264; found202.12262; HRMS (FTMS ES-), calculated for CF3O3Se, 148.95257;found 148.95217.

54761-04-5 Ytterbium(III) trifluoromethanesulfonate 2733225, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Girling, P. Ricardo; Batsanov, Andrei S.; Calow, Adam D.J.; Shen, Hong C.; Whiting, Andrew; Tetrahedron; vol. 72; 8; (2016); p. 1105 – 1113;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

13510-35-5, Indium(III) iodide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: In a 500 mL round bottom flask with a gas in- and outlet, AlCl3 (99.998 % from AlfaAesar, 50.0 g, 375 mmol) was suspended in toluene (approximately 250 mL). The flask was exposed to a pressure of PH3 until the pressure gauge read 1800 hPa under vigorous stirring. Upon formation of the CI3AI-PH3 adduct, the pressure drops and eventually the procedure has to be repeated until a clear solution is obtained and no AlCb remains undissolved in the vessel. The reaction mixture was stirred for another 30 min under PEb and then purged to the quenching system. To remove excess PEb from the solution, the flask was flushed with argon for 15 min under vigorous stirring. Toluene was added to the flask to obtain a total volume of 375 mL and thus, a 1.0 M stock solution of the CbAl-PEb adduct. 31P-NMR (101 MHz, toluene): d = -168.7 (q, PH = 374.5 Hz) ppm.

The synthetic route of 13510-35-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ETH ZURICH; GRUeTZMACHER, Hansjoerg; BISPINGHOFF, Mark; (62 pag.)WO2019/175319; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1126-58-5,1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride,as a common compound, the synthetic route is as follows.

General procedure: To a magnetically stirred solution of substituted isatin (5mmol) in 7ml of absolute ethanol, a corresponding pyridinium acetohydrazide (5mmol) and three drops of trifluoroacetic acid were successively added. The reaction mixture was heated under reflux for 3h. After spontaneously cooling the solution to room temperature, the precipitate formed was filtered, washed with absolute ether and dried in vacuo. (0032) 1-(2-(2-(1-(2-Fluorobenzyl)-2-oxoindolin-3-ylidene)hydrazinyl)-2-oxoethyl)pyridinium chloride (3a): yellow solid, mp: 215C (dec.). 2.08g (98% yield); 1H NMR (600MHz, DMSO-d6/D2O): delta 5.00 (s, 2H, CH2), 6.26 (s, 2H, CH2), 6.89 (d, J =8.0Hz, 1H, H-7), 7.15 (dd, J =7.6Hz, J =7.6Hz, 1H, H-5), 7.59 (ddd, J =7.7Hz, J =7.8Hz, J =1.0Hz, 1H, H-6), 7.64 (br. d, J =7.5Hz, 1H, H-4), 8.27 (dd, J =7.0Hz, J =6.7Hz, 2H, 3-Py), 8.74 (t, J =7.8Hz, 1H, 4-Py), 9.15 (d, J =5.6Hz, 2H, 2-Py), 12.71 (s. 1H, NH); 13C NMR (150MHz, DMSO-d6/D2O): delta 37.2, 61.0, 110.5, 115.6 (d, JCF =20.9Hz), 118.8, 120.7, 122.1 (d, JCF =13.5Hz), 123.5, 124.7, 127.7, 129.8 (d, JCF =2.4Hz), 130.0 (d, JCF =7.9Hz), 132.2, 134.9, 143.0, 146.5, 146.6, 160.1 (d, JCF =245.5Hz), 160.5, 167.6; IR (KBr) nu: 3430, 3033, 3015, 2968, 1681, 1614, 1492, 1466, 1383, 1358, 1267, 1154, 1104, 1044cm-1; Anal. Calcd (%) for C22H18ClFN4O2: C, 62.14; H, 4.24; N, 13.18; Found: C, 61.86; H, 4.17; N, 13.01; MALDI 389 [M-Cl]+.

As the paragraph descriping shows that 1126-58-5 is playing an increasingly important role.

Reference£º
Article; Bogdanov, Andrei V.; Zaripova, Ilyuza F.; Voloshina, Alexandra D.; Sapunova, Anastasia S.; Kulik, Natalia V.; Tsivunina, Irina V.; Dobrynin, Alexey B.; Mironov, Vladimir F.; Journal of Fluorine Chemistry; vol. 227; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29841-69-8,(1S,2S)-(-)-1,2-Diphenylethylenediamine,as a common compound, the synthetic route is as follows.

In a single-necked 50 mL round-bottom flask bis-aldehyde c (0.72 g, 1.5 mmol) was taken in dry MeOH (10 mL) and was stirred at 0 C, and a solution of 1S,2S-(+)-1,2-diaminocyclohexane (0.18 g,1.6 mmol)/1S, 2S-(-)-1,2-diphenylethane-1,2-diamine (0.34 g,1.6 mmol) in dry MeOH (5 mL) was added drop wise to the above solution. After complete addition, the resulting solution was further stirred at room temperature. After an interval of 12 h, solvent was completely removed under reduced pressure, and the bright yellow solid was extracted with dichloromethane (50 mL). The organic layer was washed with water (3 ¡Á 50 mL) and with brine (3 ¡Á 50 mL) and finally dried over anhydrous Na2SO4. After removal of dichloromethane under reduced pressure, the chiral ligands 1′ and 2′ purified by silica gel column chromatography (100-200 mesh) in 20% (EtOAc: Hexane) resulted in yellowish solid monomeric macrocyclic ligands, 1′ and 2′.1′: Yield 85%. m.p. 104 C. 1H NMR (500 MHz, CDCl3): delta 1.44 (18 H, s), 1.73-1.91 (8H, m), 3.23-3.25 (2H, m), 3.31-3.33 (4H, m), 3.51-3.62 (8H, m), 4.19 (2H, d, J = 11), 4.43 (2H, d, J = 11), 6.72 (2H, s), 7.27 (2H, s), 8.07 (2H, s), 11.78 (2H, br) ppm. 13C NMR (125 MHz, CDCl3): 24.3, 29.4, 32.7, 34.8, 68.5, 69.2, 70.7, 72.3, 76.4, 118.3, 127.3, 129.8, 137.4, 160.0, 166.2 ppm. FT-IR (KBr): nu 3432, 2942, 2863, 2359, 1629, 1558, 1442, 1387, 1259, 1212, 1099, 970, 845, 768, 728, 668, 594 cm-1. (c = 0.052, CH2Cl2). Anal. Calcd. for C36H52N2O6: C, 71.02; H, 8.61; N, 4.60. Found C, 71.0; H, 8.58; N, 4.58. TOF-MS (ESI+): m/z Calcd. for [C36H52N2O6] 608.81, Found 610.2 [M+H].2′: Yield 90%. m.p. 98 C. 1H NMR (200 MHz, CDCl3): delta 1.46 (18H, s), 3.30-3.36 (4H, m), 3.57-3.68 (8H, m), 4.19 (2H, d, J = 10), 4.47 (2H, d, J = 10), 4.56 (2H, s), 6.72 (2H, d, J = 1.8), 7.18-7.30 (12H, m), 8.24 (2H, s), 13.86 (2H, br) ppm. 13C NMR (50 MHz, CDCl3): 29.5, 33.9, 69.0, 70.8, 72.5, 78.6, 118.3, 127.5, 128.3, 128.4, 129.2, 137.4, 139.8, 160.1, 166.8 ppm. IR (KBr): nu 3452, 2929, 2865, 1626, 1553, 1440, 1263, 1096, 848, 726, 585, 464 cm-1. (c = 0.206, CHCl3). Anal. Calcd. for C44H54N2O6 C, 74.76; H, 7.70; N, 3.96. Found C, 74.73; H, 7.68; N, 3.93. TOF-MS (ESI+): m/z Calcd. for [C44H54N2O6] 706.91, Found 708.45 [M+H].

As the paragraph descriping shows that 29841-69-8 is playing an increasingly important role.

Reference£º
Article; Kureshy, Rukhsana I.; Roy, Tamal; Khan, Noor-Ul H.; Abdi, Sayed H.R.; Sadhukhan, Arghya; Bajaj, Hari C.; Journal of Catalysis; vol. 286; (2012); p. 41 – 50;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

DOTA(tBu)3-OH (100 mg, 0.175 mmol, 1.0 eq.) was dissolved in dry DMF (0.5 ml), HATU (66.4 mg, 0.175 mmol, 1.0 eq.) dissolved in dry DMF (0.5 ml) and Collidine (46.1 mu, 0.350 mmol, 2.0 eq.) were added. After 5 min this mixture was slowly added to a 0C cold solution of ethylendiamine (0.873 mmol. 5.0 eq.) in dry DMF (1.5 ml). After stirring for 19 h DMF was evaporated, the residual oil was dissolved in EtOAc (5 ml) and extracted with water (0.5 ml), sat. aq. NaHC03 (0.5 ml) and sat. aq. NaCl (0.5 ml). The organic layer was dried over Na2S04, evaporated and the resiude was purified by flash chromatography with DCM, DCM/methanol 20/1 and DCM/methanol 10/1 as eluents. This yielded 45 mg of mono- acylated ethylendiamine. A solution of this material (18 mg, 29 mupiiotaomicron) in dry DMF (0.2 ml) was added to a 10 min preactivated solution of SR- 142948 (20 mg, 29 mupiiotaomicron) [HATU (11.1 mg, 29 muetaiotaomicron) and DIPEA (10 mu, 58 muetaiotaomicron, 2eq.) in dry DMF (0.4 ml)]. After 15 h monoacylated ethylendiamine (9 mg, 15muiotaetaomicron1, 0.5 eq.) in dry DMF (0.1 ml) was added. 5 h later the reaction mixture was heated to 60C for 30 min. Then the solvents were evaporated and the material purified by prep. HPLC (15 to 55% B in 30 min, Agilent PLRP-S 25 x 150 mm). This yielded the title compound of formula (XVIII) (15 mg, 12mupiiotaomicron1, 40%). HPLC: Rt = 3.9 min. MS: m/z = 1282.7 ([M+H]+, calculated 1282.8) (MW = 1282.65).

The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; 3B PHARMACEUTICALS GMBH; OSTERKAMP, Frank; SMERLING, Christiane; REINEKE, Ulrich; HAASE, Christian; UNGEWIss, Jan; WO2014/86499; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

A solution of 4,7-diphenyl-1,10-phenanthroline (0.36 g, 1.10 mmol) in methanol (10 ml) was added to a solution of TlCl3*4H2O (0.42 g, 1.10 mmol) in methanol (10 ml) and the resulting colorless solution was stirred for 20 min at 40C. Suitable crystals for the X-ray diffraction measurement were obtained by methanol diffusion to a colorless solution of 1 in DMSO over two weeks (yield 0.60 g, 75.6%, m.p. > 300C). IR (CsI, cm-1): 3060 m, 2921 m, 2854 w, 1611 m, 1563 m, 1510 m, 1433 s, 1365 s, 1275 w, 1234 m, 1098 m, 1010 s, 941 m, 849 s, 759 s, 700 s, 626 w, 554 m, 491 w, 420 m, 339 m, 262 m. UV-Vis: lambdamax (DMSO, nm), 315. Anal. calcd. (%): C 43.29, H 3.05, N 3.88. Found (%): C 43.01, H 3.03, N 3.85.

The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Ghadermazi; Journal of Structural Chemistry; vol. 57; 5; (2016); p. 970 – 975; Zh. Strukt. Kim.; vol. 57; 5; (2016); p. 1020 – 1025,6;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

55515-98-5, (R)-3,3′-Dimethyl-[1,1′-binaphthalene]-2,2′-diol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 6 (682 mg, 1.0 mmol) in THF (13 mL) at -78 C was added n-BuLi (1.3 mmol, 1.67 M in hexane) dropwise over 3 min and the mixture was stirred for 10 min. PCl3 (149 mg, 1.1 mmol) was slowly added over 2 min, and the reaction was allowed to warm to room temperature. After stirring for 2 h, the solvent was thoroughly removed in vacuo, and to the residue was added THF (10 mL) and (R)-(+)-3,3?-dimethyl-1,1?-bi-2-naphthol (408 mg, 1.3 mmol), and then Et3N (212 mg, 2.1 mmol). After stirring for 10 h at ambient temperature, all the volatiles were evaporated. The mixture was dissolved in benzene (110 mL), and washed with water (100 mL), and brine (50 mL), and dried over Na2SO4. Purification by silica gel column chromatography gave a desired molecule. Date of 3 is as follows: Yield 69% as a white solid material; [alpha]27D + 378 (c 1.00, C6H6). 1H NMR (400 MHz, C6D6) delta 7.69-7.46 (m, 6H), 7.35-6.57 (m, 27H), 6.34 (dd, J = 7.4, 7.4 Hz, 1H), 2.81 (s, 3H), 1.90 (s, 3H), 1.79-1.74 (m, 12H), 1.34 (s, 3H). 13C NMR (100 MHz, C6D6) delta 150.7, 150.5, 150.4, 147.3, 146.9, 142.9, 141.77, 141.75, 141.44, 141.41, 141.2, 139.6, 139.5, 139.4, 139.2, 139.1, 139.0, 138.9, 135.9, 135.6, 135.5, 135.4, 135.3, 135.4, 133.7, 133.4, 133.2, 133.05, 132.98, 132.9, 132.7, 132.6, 132.4, 132.3, 132.1, 132.0, 131.9, 131.5, 131.1, 130.8, 130.1, 129.9, 129.3, 128.9, 128.0, 126.8, 126.45, 126.38, 126.3, 126.2, 125.8, 125.6, 124.0, 21.7, 21.61, 21.58, 21.5, 18.9 17.9. 31P NMR (162 MHz, C6D6) delta 176.4. MS (FAB) m/z: 947.77 ([M+H]+). Anal. Calcd For C69H55O2P: C, 87.50; H, 5.85. Found: C, 87.46; H, 5.77.13C NMR (100 MHz, C6D6) delta 151.4, 150.21, 150.17, 147.2, 146.8, 142.7, 142.02, 142.01, 141.9, 141.8, 141.4, 139.32, 139.27, 139.1, 139.0, 138.3, 137.9, 135.7, 135.6, 135.3, 135.2, 133.9, 133.7, 133.4, 133.33, 133.29, 132.73, 132.69, 132.53, 132.47, 132.43, 132.39, 132.1, 132.0, 131.4, 130.7, 130.0, 129.5, 129.4, 129.2, 129.0, 128.9, 128.8, 128.6, 128.5, 128.3, 127.7, 127.6, 127.0, 126.8, 126.2, 126.0, 125.5, 125.3, 124.5, 124.4, 123.8, 122.3, 21.5, 21.39, 21.36, 21.35, 21.3. 31P NMR (162 MHz, C6D6) delta 178.8. MS (ESI) m/z: 919 ([M+H]+). Anal. Calcd For C67H51O2P: C, 87.56; H, 5.59. Found: C, 87.37; H, 5.65.

55515-98-5 (R)-3,3′-Dimethyl-[1,1′-binaphthalene]-2,2′-diol 12440266, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Kamei, Toshinori; Sato, Akihiro H.; Iwasawa, Tetsuo; Tetrahedron Letters; vol. 52; 21; (2011); p. 2638 – 2641;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

7325-46-4, 2,2′-(1,4-Phenylene)diacetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2,2′-(1,4-phenylene)diacetic acid (10.0 g, 51 mmol) was dissolved in ethanol (100 ml) and the solution treated dropwise with catalytic acetyl chloride (2.5 ml). The reaction mixture was stirred at reflux for 18 hours before being allowed to cool and concentrated in vacuo. The residue was taken up in ethyl acetate (100 ml) and extracted with sodium bicarbonate solution (3¡Á50 ml) and brine (3¡Á50 ml). The organic phase was then dried (magnesium sulphate) and concentrated in vacuo. The residue was triturated with pentane to yield the title product, 11.8 g. 1HNMR (CDCl3, 400 MHz) delta: 1.26 (t, 6H), 3.57 (s, 4H), 4.12 (q, 4H), 7.21 (m, 4H) MS (electrospray): m/z 273 [M+H]+

The synthetic route of 7325-46-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Brown, Alan Daniel; James, Kim; Lane, Charlotte Alice Louise; Moses, Ian Brian; Thomson, Nicholas Murray; US2005/171147; (2005); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.111795-43-8,(R)-(+)-3,3′-Dibromo-1,1′-bi-2-naphthol,as a common compound, the synthetic route is as follows.

General procedure: Unless stated otherwise, the reaction was performed in a flamedriedflask. A mixture of BOPHY 1a (25 mg, 0.09 mmol, 1 mol equiv.)and aluminum chloride (59 mg, 0.44 mmol, 5 mol equiv.) in dry CH2Cl2(DCM, 5 mL) was refluxed under argon atmosphere until reactioncompletion (reaction monitored by TLC). The mixture was cooled downto room temperature and, then, a solution of (R)-BINOL ((R)-1,1?-binapht-2-ol, 101 mg, 0.35 mmol, 4 mol equiv.) in anhydrous acetonitrile(2 mL) was added dropwise. The resulting mixture was stirred at r.t. foradditional 6 h. After filtration and solvent evaporation under reducedpressure, the obtained residue was purified by flash chromatography(hexane/DCM 7:3) to afford 1b (24 mg, 35%) as a yellow solid.

111795-43-8 (R)-(+)-3,3′-Dibromo-1,1′-bi-2-naphthol 10765693, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Sola-Llano; Jimenez; Avellanal-Zaballa; Johnson; Cabreros; Moreno; Maroto; Muller; Banuelos; Cerdan; Garcia-Moreno; Moya, S. de la; Dyes and Pigments; vol. 170; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI